J. Macdougall

Analysis of Dose–Response Studies—E max Model

J. Macdougall, 2006 .

HAART drugs induce mitochondrial damage and intercellular gaps and gp 120 causes apoptosis

J. Cashman, J. Arthos, J. Macdougall, 2007, Cardiovascular Toxicology.

Elevated serum interleukin‐2 after gluten correlates with symptoms and is a potential diagnostic biomarker for coeliac disease

S. Acaster, J. Macdougall, J. Tye-Din, 2019, Alimentary pharmacology & therapeutics.

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis

M. Benatar, M. Bromberg, M. Pasnoor, 2020, JAMA neurology.

A prospective multicenter observational study of cell‐mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients

A. Mehta, A. Limaye, Deepali Kumar, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: Evaluation of frequency, timing, and duration.

J. Ibrahim, J. Macdougall, M. Peterschmitt, 2018, Blood cells, molecules & diseases.

Randomised clinical trial: a placebo‐controlled study of subcutaneous or intradermal NEXVAX2, an investigational immunomodulatory peptide therapy for coeliac disease

J. Macdougall, K. Truitt, Hooi C. Ee, 2019, Alimentary pharmacology & therapeutics.

Epitope-Specific Immunotherapy Targeting CD4-Positive T Cells in Celiac Disease: Safety, Pharmacokinetics, and Effects on Intestinal Histology and Plasma Cytokines with Escalating Dose Regimens of Nexvax2 in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

J. Andrews, J. Macdougall, L. Williams, 2017, EBioMedicine.

Utility of the T-SPOT®.TB test's borderline category to increase test resolution for results around the cut-off point.

J. Macdougall, W. Cruikshank, K. Rego, 2018, Tuberculosis.

Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles

D. Gaudet, R. Hegele, E. Bruckert, 2019, Journal of the Endocrine Society.

Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial

R. Finkel, W. Rooney, W. Triplett, 2021, Neuromuscular Disorders.